Latest Breaking News On - Kentaro tahara - Page 3 : comparemela.com
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,
GermanyCambridgeCambridgeshireUnited-kingdomLondonCity-ofJapanSeoulSoult-ukpyolsiSouth-koreaNew-yorkUnited-states